Treatment of Cirrhosis of the Liver

Introduction to Cirrhosis Treatment

The American College of Physicians recommends that the treatment of cirrhosis should focus on addressing the underlying cause, preventing disease progression, and managing complications through a comprehensive approach that includes medication, lifestyle modifications, and regular monitoring to improve survival and quality of life 1

The American Association for the Study of Liver Diseases recommends that complete cessation of alcohol consumption is the cornerstone of treatment for alcoholic cirrhosis and can lead to dramatic improvement in the reversible component of alcoholic liver disease, with patients with Child-Pugh class C cirrhosis who stop drinking having approximately 75% 3-year survival, while those who continue drinking have 0% survival at 3 years 2, 3
The European Association for the Study of the Liver recommends that antiviral therapy with tenofovir, entecavir, or peginterferon-α can improve liver function and reduce complications in patients with HBV-related cirrhosis 4, 5

The American Gastroenterological Association recommends that dietary sodium restriction (2000 mg/day or 88 mmol/day) is essential for managing ascites in patients with cirrhosis 2, 3, 7
The European Society for Clinical Nutrition and Metabolism recommends that the nutritional intake for cirrhotic patients should include carbohydrate: 2-3 g/kg/day, protein: 1.2-1.5 g/kg/day, and caloric intake: 35-40 kcal/kg/day 7

The American Association for the Study of Liver Diseases recommends that oral diuretics are the mainstay of treatment alongside sodium restriction for ascites management in patients with cirrhosis 2, 3
The International Club of Ascites recommends that large-volume paracentesis (LVP) with albumin replacement is recommended for refractory ascites in patients with cirrhosis 1

The American College of Physicians recommends that consider telemedicine and remote monitoring technologies to help with early detection of complications and reduce hospital readmissions in patients with cirrhosis 6, 1

The American Society of Transplant Surgeons recommends that liver transplantation is potentially optimal therapy for small-size, otherwise resectable hepatocellular carcinoma in patients with moderate to severe cirrhosis (Child-Pugh class B or C) 8

The American Society of Clinical Oncology recommends that only 10-30% of patients initially presenting with hepatocellular carcinoma will be eligible for surgery, and surgery in patients with underlying cirrhosis can be associated with substantial morbidity and mortality (30-50% in Child-Pugh class B or C, but only 5-10% in Child-Pugh class A) 8
The European Association for the Study of the Liver recommends that patients with MELD score < 9 have significantly lower mortality rates when undergoing resection of hepatocellular carcinoma 8